Jack U. Flanagan

8.0k citations

85 papers · 5.9k · 1 hit paper · h-index 31

Impact in

Pharmacology top 0.5%
- Pharmacogenetics and Drug Metabolism
Molecular Biology top 2%
- Glutathione Transferases and Polymorphisms
- Genomics, phytochemicals, and oxidative stress
- Epigenetics and DNA Methylation
- PI3K/AKT/mTOR signaling in cancer

Papers in

Molecular Biology 53
- PI3K/AKT/mTOR signaling in cancer 16
- Glutathione Transferases and Polymorphisms 12
- Genomics, phytochemicals, and oxidative stress 12
- Protein Kinase Regulation and GTPase Signaling 6
Oncology 13

Co-authors: John D. Hayes (4 shared papers)Ian R. Jowsey (3 shared papers)William A. Denny (24 shared papers)Michael P. Hay (6 shared papers)Peter R. Shepherd (19 shared papers)C. Roland Wolf (5 shared papers)Michael J. Sutcliffe (5 shared papers)Mark J. I. Paine (5 shared papers)
Journals: Bioorganic & Medicinal Chemistry (12 papers)Biochemical Journal (8 papers)Journal of Medicinal Chemistry (5 papers)Journal of Biological Chemistry (5 papers)European Journal of Medicinal Chemistry (4 papers)
Partner nations: New Zealand Australia United States

In The Last Decade

Jack U. Flanagan

84 papers receiving 5.8k citations

Jack U. Flanagan's Hit Papers

align trajectories log scale

GLUTATHIONE TRANSFERASES 2004 · 2.9k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2004 The Annual Review of Pharmacology and Toxicology

Peers

Countries citing papers authored by Jack U. Flanagan

Since Specialization

Citations

This map shows the geographic impact of Jack U. Flanagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack U. Flanagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack U. Flanagan more than expected).

Fields of papers citing papers by Jack U. Flanagan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jack U. Flanagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack U. Flanagan. The network helps show where Jack U. Flanagan may publish in the future.

Co-authors

The 25 scholars most cited alongside Jack U. Flanagan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jack U. Flanagan Line = papers co-authored together Jack U. Flanagan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 85 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	GLUTATHIONE TRANSFERASES The Annual Review of Pharmacology and Toxicology ·John D. Hayes, Jack U. Flanagan, Ian R. Jowsey Hit paper breakdown →	2004	2917
2	Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality Science Translational Medicine ·Denise A. Chan, Patrick D. Sutphin, Phuong Nguyen, Sandra Turcotte, Edwin W. Lai, Alice Banh, Gloria E. Reynolds, Jen‐Tsan Chi, Jason Wu, David E. Solow-Cordero, Muriel Bonnet, Jack U. Flanagan, Donna M. Bouley, Edward E. Graves, William A. Denny, Michael P. Hay, Amato J. Giaccia	2011	461
3	Human theta class glutathione transferase: the crystal structure reveals a sulfate-binding pocket within a buried active site Structure ·Jamie Rossjohn, William J. McKinstry, Aaron J. Oakley, Denis Verger, Jack U. Flanagan, Gareth Chelvanayagam, Kian-Leong Tan, (unknown), Michael W. Parker	1998	133
4	A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types Biochemical Journal ·Stephen M. F. Jamieson, Jack U. Flanagan, Sharada Kolekar, Christina M. Buchanan, Jackie D. Kendall, Woo Jung Lee, Gordon W. Rewcastle, William A. Denny, Ripudaman Singh, James M. Dickson, Bruce C. Baguley, Peter R. Shepherd	2011	123
5	Selenium-containing green tea has higher antioxidant and prebiotic activities than regular green tea Food Chemistry ·A.L. Molan, Jack U. Flanagan, Wenhua Wei, Paul J. Moughan	2008	122
6	Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed Journal of Structural Biology ·Y. Yosaatmadja, Shevan Silva, James M. Dickson, Adam V. Patterson, Jeff B. Smaill, Jack U. Flanagan, Mark J. McKeage, C.J. Squire	2015	111
7	Targeting growth hormone function: strategies and therapeutic applications Signal Transduction and Targeted Therapy ·Man Lu, Jack U. Flanagan, Ries J. Langley, Michael P. Hay, Jo K. Perry	2019	107
8	Residues Glutamate 216 and Aspartate 301 Are Key Determinants of Substrate Specificity and Product Regioselectivity in Cytochrome P450 2D6 Journal of Biological Chemistry ·Mark J. I. Paine, Lesley A. McLaughlin, Jack U. Flanagan, Carol A. Kemp, Michael J. Sutcliffe, Gordon C. K. Roberts, C. Roland Wolf	2003	95
9	Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474) Journal of Medicinal Chemistry ·Gordon W. Rewcastle, Swarna A. Gamage, Jack U. Flanagan, Raphaël Frédérick, William A. Denny, Bruce C. Baguley, Philip Kestell, Ripudaman Singh, Jackie D. Kendall, Elaine S. Marshall, Claire L. Lill, Woo Jung Lee, Sharada Kolekar, Christina M. Buchanan, Stephen M. F. Jamieson, Peter R. Shepherd	2011	92
10	Mammalian class Sigma glutathione S-transferases: catalytic properties and tissue-specific expression of human and rat GSH-dependent prostaglandin D2 synthases Biochemical Journal ·Ian R. Jowsey, Anne M. Thomson, Jack U. Flanagan, Paul R. Murdock, Gary B.T. Moore, David J. Meyer, Gregory Murphy, Stephen A. Smith, John D. Hayes	2001	78
11	An Inflammatory Role for the Mammalian Carboxypeptidase Inhibitor Latexin: Relationship to Cystatins and the Tumor Suppressor TIG1 Structure ·Anna Aagaard, Pawel Listwan, Nathan Cowieson, Thomas Huber, Timothy Ravasi, Christine A. Wells, Jack U. Flanagan, Stuart Kellie, David Hume, Boštjan Kobe, Jennifer L. Martin	2005	70
12	Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development Trends in Pharmacological Sciences ·Julia K. Archbold, Jack U. Flanagan, Harriet A. Watkins, Joseph J. Gingell, Debbie L. Hay	2011	67
13	Sequence–Structure–Function Classification of a Catalytically Diverse Oxidoreductase Superfamily in Mycobacteria Journal of Molecular Biology ·F. Hafna Ahmed, Paul D. Carr, Brendon M. Lee, Livnat Afriat‐Jurnou, A. Elaaf Mohamed, Nan-Sook Hong, Jack U. Flanagan, Matthew C. Taylor, Chris Greening, Colin J. Jackson	2015	64
14	Why Is Quinidine an Inhibitor of Cytochrome P450 2D6? Journal of Biological Chemistry ·Lesley A. McLaughlin, Mark J. I. Paine, Carol A. Kemp, Jean‐Didier Maréchal, Jack U. Flanagan, C. J. Ward, Michael J. Sutcliffe, Gordon C. K. Roberts, C. Roland Wolf	2005	63
15	Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite Biochemical Journal ·Jack U. Flanagan, Jean‐Didier Maréchal, Richard J. Ward, Carol A. Kemp, Lesley A. McLaughlin, Michael J. Sutcliffe, Gordon C. K. Roberts, Mark J. I. Paine, C. Roland Wolf	2004	62
16	Validation of Model of Cytochrome P450 2D6: An in Silico Tool for Predicting Metabolism and Inhibition Journal of Medicinal Chemistry ·Carol A. Kemp, Jack U. Flanagan, Annamaria J. van Eldik, Jean‐Didier Maréchal, C. Roland Wolf, Gordon C. K. Roberts, Mark J. I. Paine, Michael J. Sutcliffe	2004	60
17	Crystal Structures of Three Classes of Non-Steroidal Anti-Inflammatory Drugs in Complex with Aldo-Keto Reductase 1C3 PLoS ONE ·Jack U. Flanagan, Y. Yosaatmadja, Rebecca Teague, Matilda Z. L. Chai, A.P. Turnbull, C.J. Squire	2012	59
18	Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy Cell chemical biology ·Janine N. Copp, Alexandra M. Mowday, Elsie M. Williams, Christopher P. Guise, Amir Ashoorzadeh, Abigail V. Sharrock, Jack U. Flanagan, Jeff B. Smaill, Adam V. Patterson, David F. Ackerley	2017	58
19	Mammalian class Sigma glutathione S-transferases: catalytic properties and tissue-specific expression of human and rat GSH-dependent prostaglandin D2 synthases Biochemical Journal ·Ian R. Jowsey, Anne M. Thomson, Jack U. Flanagan, Paul R. Murdock, Gary B.T. Moore, David J. Meyer, Gregory Murphy, Stephen A. Smith, John D. Hayes	2001	54
20	4-Pyridylanilinothiazoles That Selectively Target von Hippel−Lindau Deficient Renal Cell Carcinoma Cells by Inducing Autophagic Cell Death Journal of Medicinal Chemistry ·Michael P. Hay, Sandra Turcotte, Jack U. Flanagan, Muriel Bonnet, Denise A. Chan, Patrick D. Sutphin, Phuong Nguyen, Amato J. Giaccia, William A. Denny	2009	53

About Jack U. Flanagan

Jack U. Flanagan is a scholar working on Molecular Biology, Oncology, Genetics, Organic Chemistry and Cell Biology, having authored 85 papers that have together received 5.9k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (16 papers), Glutathione Transferases and Polymorphisms (12 papers), Genomics, phytochemicals, and oxidative stress (12 papers), Chronic Lymphocytic Leukemia Research (9 papers), Pharmacogenetics and Drug Metabolism (8 papers), Aldose Reductase and Taurine (7 papers), Tryptophan and brain disorders (7 papers) and Protein Kinase Regulation and GTPase Signaling (6 papers). The work is most often cited by research in Pharmacology (575 citations), Molecular Biology (3.6k citations), Biological Psychiatry (106 citations), Biochemistry (295 citations) and Cancer Research (559 citations). Jack U. Flanagan has collaborated with scholars based in New Zealand, Australia and United States. Frequent co-authors include John D. Hayes, Ian R. Jowsey, William A. Denny, Michael P. Hay, Peter R. Shepherd, C. Roland Wolf, Michael J. Sutcliffe, Mark J. I. Paine, Gordon C. K. Roberts and Muriel Bonnet. Their work appears in journals such as Bioorganic & Medicinal Chemistry, Biochemical Journal, Journal of Medicinal Chemistry, Journal of Biological Chemistry and European Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Jack U. Flanagan

Impact in

Papers in i

In The Last Decade

Jack U. Flanagan

Jack U. Flanagan's Hit Papers

Peers

Countries citing papers authored by Jack U. Flanagan

Fields of papers citing papers by Jack U. Flanagan

All Works

About Jack U. Flanagan

Explore authors with similar magnitude of impact

Papers in